In “Risks and Strategies for Filter Reuse (Part I),” we explored the critical role of filters in the pharmaceutical, biotechnology, and vaccine industries, as well as the potential risks and challenges associated with reusing sterilizing-grade filters, analyzing the pros and cons of various reuse methods. This second part focuses on regulatory requirements and industry guidelines, providing a detailed interpretation of specific regulations regarding filter reuse from the FDA, EU GMP, and China GMP. We will discuss how to achieve the reuse of liquid filters through scientific methods and rigorous validation within a strict regulatory framework.
Regulatory Requirements and Guidelines for Filter Reuse
FDA cGMP Guideline on Sterile Drug Products Produced by Aseptic Processing (2004)
Sterilizing filters should be routinely discarded after processing of a single lot. However, in those instances when repeated use can be justified, the sterile filter validation should incorporate the maximum number of lots to be processed. Integrity testing of the filter(s) can be performed prior to processing, and should be routinely performed post-use. It is important that integrity testing be conducted after filtration to detect any filter leaks or perforations that might have occurred during the filtration…
EC GMP Annex 1: Manufacture of Sterile Medicinal Products (2022)
Filter Integrity
The integrity of the sterilised filter assembly should be verified by integrity testing before use (pre-use post sterilisation integrity test or PUPSIT), to check for damage and loss of integrity… A sterilising grade filter that is used to sterilise a fluid should be subject to a non-destructive integrity test post-use prior to removal of the filter from its housing, including bubble point, diffusive flow, water intrusion, or pressure hold test.
The integrity of critical sterile gas and air vent filters (that are directly linked to the sterility of the product) should be verified by testing after use…
Reuse
Liquid sterilising grade filters should be discarded after the processing of a single batch and the same filter should not be used continuously for more than one working day unless such use has been validated.
Compatibility
The adsorption and reactivity of the product with product contact surfaces should be evaluated under process conditions.
FDA 21 CFR 211.65(a) on cGMP for Finished Pharmaceuticals
Equipment shall be constructed so that surfaces that contact components, in-process materials, or drug products shall not be reactive, additive, or absorptive so as to alter the safety, identity, strength, quality, or purity of the drug product beyond the official or other established requirements.
China GMP (2010 Revision)
Article 3: These regulations, as part of the quality management system, constitute the basic requirements for pharmaceutical production management and quality control. They aim to minimize risks such as contamination, cross-contamination, confusion, and errors during production, ensuring the continuous and stable production of pharmaceuticals that meet their intended use and registration requirements.
Article 74: Production equipment must not adversely affect drug quality. Surfaces of production equipment in direct contact with drugs must be smooth, clean, easy to clean or disinfect, and corrosion-resistant. They must not chemically react with the drug, adsorb the drug, or release substances into the drug.
Industry Standards/Recommendations
PDA Technical Report No. 26 (2008)
Sterilizing filters should routinely be discarded after the processing of a single lot. However, in instances where repeated use can be justified, the sterile filter validation, including integrity testing, bacterial challenge, and cleaning, should incorporate the maximum number of lots to be processed.
Filter reuse is typically not practical or recommended for pharmaceutical purposes. However, if a sterilizing-grade filter is reused, justification should be provided, and reuse parameters should be validated.
Filter reuse is generally impractical and not recommended for pharmaceutical applications. However, if a sterilizing-grade filter is to be reused, justification must be provided, and reuse parameters must be validated.
FDA Warning Letter Case Studies
Sterile Ophthalmic Preparations (August 2005): “Based on the review report, you continue to reuse filters as long as they meet the manufacturer’s integrity test criteria or your internal maximum usage limit of 50 cycles. Our concern is whether the filter remains effective after 50 reuse cycles and autoclaving. To assess the impact of 50 reuse cycles, we require bacterial retention validation studies comparing new filters with filters subjected to 50 use cycles. Furthermore, we are uncertain whether you have conducted extractables and leachables testing on the filters…”
Sterile Drug Product Manufacturing (September 1999): “Failure to adequately validate the reuse of filters across multiple injectable products, coupled with insufficient cleaning validation data, prevents assurance that no product residues remain. Consequently, the risk of cross-contamination is considered high.”
In summary, regulations and industry standards clearly state that sterilizing-grade filters should typically be discarded after single-batch processing. However, reuse may be considered if supported by sufficient validation. Post-use integrity testing is mandatory to ensure filter safety and efficacy, and critical sterile gas filters must also undergo post-use integrity testing. Additionally, product-filter compatibility must be evaluated to ensure drug quality is not compromised. FDA warning letters emphasize the importance of bacterial retention and extractables/leachables testing when reusing filters to mitigate cross-contamination risks.
Risks of Liquid Filter Reuse
A redundant filtration process design may involve single-use of the final sterilizing-grade filter, allowing upstream process filtration operations to utilize the filter in subsequent batches during reuse scenarios.
When reusing filters, the criticality of sterility assurance and other potential impacts on the filtrate must be evaluated separately.
Potential risks associated with filter reuse include: - Filter clogging - Integrity failure - Increased leachables - Bacterial penetration - Endotoxin exceedance
Risk Classification:
• Low Risk: Sterility assurance is not required at the filtrate side (e.g., particulate removal, bioburden control).
• Higher Risk: Sterilizing-grade filtration; products prone to microbial growth; challenging process conditions (high differential pressure, high temperature, extended duration); use of complex cleaning agents.
Control Measures and Documentation for Specific Product/Process Reuse:
• Clear and unique labeling for reused filters
• Tracking of reuse cycles
• Trend monitoring of integrity data
• Pharmaceutical quality monitoring data
• Sterilization validation for reused filters
• Other relevant controls
Validation of Filter Reuse
Validation of filter reuse should encompass the following aspects:
• Determination of the maximum number of reuse cycles
• Assessment of microbial retention efficacy after reuse
• Cleaning process validation
• Confirmation that microbial levels in the solution meet specifications
• Sterilization process validation for the filter
• Compatibility testing between the product and cleaning agents
• Other relevant validation items
Rinsing and Cleaning
Drying
Storage
Determination of Maximum Reuse Cycles
Summary
This article analyzed regulatory requirements for filter reuse, including provisions from the FDA, EU GMP, and China GMP. Sterilizing-grade filters may be considered for reuse when supported by sufficient validation, and post-use integrity testing is mandatory to ensure safety and efficacy. We also discussed potential risks associated with reuse, such as filter clogging, integrity failure, increased leachables, bacterial penetration, and endotoxin exceedance, along with corresponding control measures. Furthermore, we explored critical operational steps including rinsing, cleaning, drying, storage, and the determination of maximum reuse cycles.
The next article will provide an in-depth analysis of the limitations of integrity testing for filter reuse, economic and compliance assessments, and practical action guidelines.